DESVENLAFAXINE DIN 02535106
Health Canada record
| Active ingredient(s) | DESVENLAFAXINE 50 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AX23 DESVENLAFAXINE |
| Original market date | 25-May-2023 |
| Current status date | 25-May-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sanis Health Inc. — licence 101796, currently licensed, last inspection rating I (2024-07-23).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DESVENLAFAXINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02466996 | APO-DESVENLAFAXINE | APOTEX INC | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02466988 | APO-DESVENLAFAXINE | APOTEX INC | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
| 02554976 | DESVENLAFAXINE | SIVEM PHARMACEUTICALS ULC | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02535114 | DESVENLAFAXINE | SANIS HEALTH INC | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02543680 | DESVENLAFAXINE | PRO DOC LIMITEE | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02554968 | DESVENLAFAXINE | SIVEM PHARMACEUTICALS ULC | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
| 02543672 | DESVENLAFAXINE | PRO DOC LIMITEE | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
| 02538423 | SANDOZ DESVENLAFAXINE | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | DESVENLAFAXINE 100 MG | Marketed |
| 02538415 | SANDOZ DESVENLAFAXINE | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | DESVENLAFAXINE 50 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30065 | 2023-02-06 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement Between Two Companies |
International API supply for DESVENLAFAXINE
26 active FDA Drug Master Files.
Request a quote for DESVENLAFAXINE